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ABSTRACT
The COVID-19 pandemic adversely affected the lives of most Americans. People with
Substance Use Disorder (SUD) were particularly vulnerable to the negative effects brought on by
the pandemic. This study explored the increase in deaths due to opioid overdose during the
pandemic exacerbated by factors such as increased stress, decrease in treatment options due to
social distancing requirements and facility closures, social isolation, and an increase in spare
time. Access to treatment for opioid use disorder (OUD) was interrupted by the measures meant
to mitigate the spread of COVID-19. Through a systematic review of current literature, it was
demonstrated that existing patients were able to maintain access to care, while few new patients
were able to initiate treatment. Telehealth proved to be a vital means of assuring PWUD were
able to access life-saving treatment amid a pandemic. Further research is needed to determine
whether SUD treatment measures during the COVID-19 pandemic warrants changing the
policies long term.
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INTRODUCTION
Since the late 1990s, over 500,000 Americans have died from an opioid overdose (CDC,
2021). The National Center for Drug Abuse Statistics estimates an average of 136 Americans die
every day from overdose deaths related to prescription opioids (NCDAS, 2022). The opioid
epidemic was set in motion when pharmaceutical companies began to manufacture substantial
amounts of opioid-based pain killers. Healthcare professionals were assured that these pain
killers would not cause their patients to become addicted (U.S. Dept HHS, 2017). There have
been four waves of overdoses due to three categories of opioids: prescription opioid pills, heroin,
and synthetic opioids such as fentanyl (Ciccarone, 2019). Overdoses related to prescription
opioids, such as hydrocodone and oxycodone, began rising in 1999 and have steadily increased.
The rise of heroin overdose deaths started the second wave of the opioid epidemic in 2007
(Ciccarone, 2019). In 2015, heroin overdose deaths exceeded the total number of deaths from
prescription opioid overdose (Ciccarone, 2019). The third wave of opioid overdose commenced
in 2013 when fentanyl mixed with substances such as prescription pills, heroin, and cocaine
emerged (CDC, 2021). Recent data suggest that we are currently in the midst of a fourth wave
characterized by overdoses due to fentanyl-contaminated products and psychostimulants
(Jenkins, 2021). The fourth wave of the opioid epidemic is largely contributed to an increase in
the production of synthetic drugs by the Mexican drug cartel (Press, 2021). Evidence in the
United States suggests that 64,000 overdose deaths in 2021 were due to the cartels adding
fentanyl into counterfeit opioids (Press, 2021). The data presented in “Trends and Geographic
Patterns in Drug and Synthetic Opioid Overdose Deaths” illustrates the rates of overdose in the
United States from 2013 to 2019, along with the steady increase in overdoses associated with
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psychostimulants (Mattson et al., 2021). However, the emergence of a global pandemic in 2020
has worsened the opioid epidemic and changed the current methods of treating addiction.
COVID-19, a disease caused by a strain of coronavirus known as SARS-CoV-2, emerged
in December 2019. Almost 6 million people have perished from COVID-19 worldwide. Over
951,000 people have died in the U.S. alone. Officials at the local, state, and federal levels
introduced a variety of policies attempting to mitigate the spread of COVID-19 in March of
2020. Stay-at-home orders were put in place, encouraging only essential workers to leave their
homes (Rosenbaum et al., 2021). Social distancing was implemented which required those who
do not live in the same household to maintain a distance of six feet between them. Individuals
were also required to wear a mask when not social distancing as another method of reducing
COVID-19 transmission. Unintended consequences of these mitigation measures included
economic distress, social isolation, and fear of virus transmission.
COVID-19 has adversely affected the lives of Americans in many ways. Economic
distress can lead to feelings of loneliness, anxiety, and depression under normal circumstances.
These feelings of hopelessness coupled with the social isolation brought on by the pandemic
have created the perfect storm for many with substance use disorder (SUD). In addition, the
social restrictions of the pandemic (e.g., stay-at-home orders and lockdowns) and fear of virus
transmission have resulted in the disruption of treatment for many people who have SUD.
COVID-19 exacerbated the ongoing national epidemic of opioid-driven overdose. This paper
will examine how the opioid epidemic was affected overall, measures used to treat opioid
addiction, and how they evolved throughout the COVID-19 pandemic.
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LITERATURE REVIEW
According to the American Society of Addiction Medicine (ASAM), addiction is defined
as “a treatable, chronic medical disease involving complex interactions among brain circuits,
genetics, the environment, and an individual’s life experiences” (ASAM Board of Directors,
Definition of Addiction 2011). Opioids are a class of drugs that bind to the central nervous
system receptors (SAMHSA, 2020). Opioids prescribed for pain include morphine, codeine,
oxycodone, hydrocodone, etc., while the illegal opioids include heroin, fentanyl, and fentanyl
analogs (SAMHSA, 2020). Repeated use of opioids can lead the brain to depend on the
substance to function normally and can lead to serious consequences, including death. At the
beginning of 2020, it was hypothesized that individuals with SUD would have an elevated risk of
opioid overdose during the COVID-19 pandemic (Imtiaz et al., 2021).
The measures implemented to reduce the spread of COVID-19 have created economic
distress, social isolation, and fear of virus transmission, especially for those with substance use
disorder (SUD). Before the pandemic, people who use drugs (PWUD) were especially vulnerable
to financial insecurity and economic distress. During the pandemic, these situations worsened as
many people lost their jobs. Participants of a study conducted in late 2020 “indicated that time at
home due to job loss or stay-at-home orders resulted in more free time and left them feeling
bored” (Bolinski et al., 2022). Many admitted to using drugs more frequently due to spare time.
In addition, COVID-19 mitigation methods required anonymous meetings and other support
groups to be eliminated (Iacono, 2022). The social isolation brought on by the pandemic was
especially detrimental to people with SUD as it cut them off from family, friends, and those in
their support groups. Social distancing measures have allowed PWUD to do so alone, with
limited opportunities for others to respond in the event of an overdose (Imtiaz et al., 2021).
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Social isolation is known to be a trigger for relapse (Rosenbaum et al., 2021). To avoid the risk
of exposure to COVID-19, many people avoided seeking medical treatment for opioid addiction
and overdose (Holland et al., 2021). Individuals with SUD may have experienced increased
mental distress due to unemployment, quarantine, and fear of susceptibility to COVID-19.
Mental distress caused by the disruption to all aspects of life is a leading concern for
people who use drugs (Warfield et al., 2021). Disasters of a large scale are often followed by an
increase in mental health-related illnesses like depression and substance use disorder (Galea et
al., 2021). For instance, “5% of the population affected by Hurricane Ike in 2008 met the criteria
for major depressive disorder in the month after the hurricane; 1 out of 10 adults in New York
City showed signs of the disorder in the month following the 9/11 attacks. And almost 25% of
New Yorkers reported increased alcohol use after the attacks,” (Galea et al., 2021). Feelings of
loneliness, anxiety, and depression are factors that can lead to overdose as PWUD search for a
way to ease their pain. Individuals with substance use disorder require a support system, which
many did not have access to throughout the pandemic due to stay-at-home orders/lockdowns
(Rosenbaum et al., 2021). These feelings, “coupled with a lack of resources for social distancing
and hygiene,” leave this population more susceptible to contract COVID-19 (Rosenbaum et al.,
2021).
According to current literature, public health resources are inadequate to deal with the
increased demand for mental health services (Anjum et al., 2020). The United States has an
average of 16.6 psychiatrists per 100,000 people, with even less access in rural areas (KFF,
2021). This inadequate number of mental health professionals is of particular concern because a
survey conducted in April 2020 found that 1-in-7 U.S. adults reported serious psychological
distress (Jones et al., 2021). During peak COVID-19 transmission, there were also reports of
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increased substance use to cope with stress or emotions associated with the pandemic (Jones et
al., 2021).
Along with mental health comorbidities, PWUD often have underlying health
conditions, such as cardiovascular and respiratory diseases, HIV, Hepatitis C, etc. that make
them especially vulnerable to COVID-19 (Becker & Fiellin, 2020). Those with respiratory
challenges from substance use disorder face an increased risk of infection by the virus because
COVID-19 is a highly infectious respiratory disease. People are also more likely to die from
COVID-19 if they have chronic health conditions like high blood pressure, asthma, or COPD
(chronic obstructive pulmonary disease) that are commonly associated with opioid or substance
use disorder (CDC, 2020). Since people with SUD are often homeless or live in congregate
living arrangements where it is difficult to maintain physical distance, it was suggested that these
individuals would be more likely to contract COVID-19 (King et al., 2021). Living in places
with large groups of people such as shelters, sober living homes, and detention facilities is
another factor that can increase the risk of dying from COVID-19 for people who use drugs.
Access to care for Opioid Use Disorder (OUD) and SUD was disrupted due to stay-athome orders, health care office closures, and the cessation of in-person treatment (Jones et al.,
2021). Studies suggest that small inconsistencies in access to medication can significantly impact
a patient’s outcome (Currie et al., 2021). Treatment options have conventionally required inperson counseling, examination, and dispensing of medication (Leppla & Gross, 2020). Changes
in policy at the onset of the pandemic allowed providers to prescribe medications used for the
treatment of opioid use disorder (MOUD) including methadone, buprenorphine, and naltrexone
through telemedicine (Cales et al., 2022). These drugs have been shown to decrease illicit drug
use and risk of overdose (Pearce et al., 2020). Rates of opioid overdose were expected to
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increase based on reduced access to these medications in addition to naloxone, which reverses
opioid overdose (Jones et al., 2021).
Methadone is an opioid agonist and acts to reduce the cravings and symptoms associated
with opioid withdrawal maintenance (SAMHSA, 2022a). Prior to the COVID-19 pandemic,
strict regulations were in place regarding methadone dispensing. Patients undergoing methadone
treatment were required to go to a Substance Abuse and Mental Health Service Administration
(SAMHSA) certified opioid treatment program (OTP) to have their medication administered
(Joudrey et al., 2021). Following the introduction of social distancing guidelines, SAMHSA and
the U.S. Drug Enforcement Agency (DEA) took steps to ease the restrictions surrounding
MOUD (Iacono, 2022). New guidelines were established allowing OTPs to dispense a 28-day
supply of methadone to take home for all patients deemed stable and a 14 day supply for “less”
stable patients (Henry et al., 2022). Before these new guidelines, for a dosage of this size to be
dispensed, patients would have been required to be enrolled in an OTP for 2 years (Iacono,
2022). Although methadone treatment still requires an initial in-person visit, these changes were
expected to increase access to life-saving treatment during social isolation.
Buprenorphine, unlike methadone, can be prescribed by a variety of clinicians in different
settings. It is a partial agonist that lessens withdrawal symptoms and dependency on opioids
(Cremer et al., 2022). The Ryan Haight Online Pharmacy Consumer Protection Act of 2008
regulates online prescriptions and the use of telehealth for prescribing controlled substances
(Shore, 2022). The act requires a clinician prescribing a controlled substance to first complete an
in-person exam which limits the utilization of telehealth to initiate buprenorphine treatment
(Shore, 2022). After COVID-19 was declared a pandemic in March 2020, SAMHSA loosened
the restrictions regarding initiation of buprenorphine treatment (Livingston et al., 2021).
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Treatment programs were permitted to dispense buprenorphine without the initial in-person
evaluation. These changes in regulation were hypothesized to favor new patients on
buprenorphine and provide an advantage over other treatments in terms of social distancing
(Leppla & Gross, 2020).
To prevent relapse following medically supervised withdrawal from opioids, naltrexone
is used for treatment (SAMHSA, 2022b). Naltrexone is an opioid antagonist and can be
prescribed by any licensed practitioner as an extended-release intramuscular injectable or as a
pill (SAMHSA, 2022b). The naltrexone injection must be injected monthly by a practitioner in
an OTP or substance abuse treatment facility (Krawczyk et al., 2021). Due to the social
distancing guidelines, office closures and limited staff required many treatment providers to offer
the naltrexone injection once every 45 days instead of every 30 days (Cremer et al., 2022). This
likely left patients more susceptible to relapse and overdose (Cremer et al., 2022).
Syringe service programs (SSPs) and harm reduction services are essential services that
help PWUD lessen infectious disease transmission and risky drug-using behaviors (Wenger et
al., 2021). SSPs provide safe disposal and access to sterile syringes or other equipment, as well
as providing connections to SUD treatment and access to naloxone (Wenger et al., 2021). The
majority of SSPs in the United States offer naloxone education to friends, family, and other
laypersons (Wenger et al., 2021). There is substantial evidence that SSPs are effective in
preventing overdose deaths (Wenger et al., 2021). The COVID-19 mitigation measures resulted
in a lack of funding and created staffing shortages at many harm reduction service facilities.
Facilities that temporarily closed or remained open employed evidence-based strategies to
continue providing care to those with SUD. One study of 18 SSPs, qualitatively analyzed the
methods that SSPs used during the COVID-19 pandemic to ensure patients still had access to
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care. Following the stay-at-home orders, many of the 18 SSPs reported the number of people
they were helping significantly decreased (Wenger et al., 2021). Some of the innovative
approaches the participating SSPs adopted included setting up outdoor sites, creating
handwashing stations, prepackaging supplies, delivering naloxone and other supplies, and
distributing supplies via mail order (Wenger et al., 2021). These delivery methods not only
allowed more naloxone to be distributed to vulnerable populations, but they also allowed
individuals to receive treatment/supplies that previously would not have been obtained due to the
stigma associated with being a person who uses drugs.
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METHODS
A systematic search of articles in electronic databases was conducted beginning in April
2021 and concluding in March 2022. Studies were eligible for inclusion if they assessed opioid
overdose deaths during the COVID-19 pandemic in a quantitative or qualitative manner. Search
terms included, but were not limited to, the impact of COVID-19 pandemic, substance use
disorder, opioid overdoses, the opioid epidemic and COVID-19, methadone access, syringe
service programs, addiction treatment, and COVID-19.

RESULTS: ANALYSIS OF EMPIRICAL STUDIES
At the beginning of the COVID-19 pandemic, it was predicted that people with SUD
would face a greater risk of opioid overdose (Imtiaz et al., 2021). According to a systematic
review of nine studies regarding overdose rates, deaths from overdose “were 9 to 50% higher
between the periods of March 2020 to July 2020 compared with between the periods of
December 2019 to March 2020…” (Imtiaz et al., 2021). This data indicates an increase in the
average rate of overdoses from 680 deaths per month in the twelve months prior to the pandemic,
to 2348 overdose deaths per month in the twelve months following the outbreak of COVID-19
(Imtiaz et al., 2021). It is clear that opioid overdose deaths were increasing prior to the arrival of
COVID-19 and continued to climb after the global pandemic was declared (Imtiaz et al., 2021).
Trends in mental health and opioid overdose were assessed using studies related to
emergency services data. These trends allow the impact of COVID-19 on rates of overdose to be
determined. The data presented by Slavova et al. compared EMS (emergency medical services)
runs in the periods before and after the onset of the pandemic in Kentucky. As evident in this
study, “EMS runs for opioid overdose have increased both in the rate of transportation to ED
[emergency department] and, critically, in the number of those who were treated on the scene
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and refused transportation to ED” (Slavova et al., 2020). In the same period, EMS runs for all
causes other than overdose decreased by over twenty percent, giving an early indication of the
increase in overdoses during the pandemic (Slavova et al., 2020). On the other hand, a study
conducted in Philadelphia, observed a 6.8% decrease in overdoses from the period before stayat-home orders, to the period during the stay-at-home orders (Rosenbaum et al., 2021). While the
Philadelphia study shows a decrease in opioid overdoses presented in emergency departments,
COVID-19 likely decreased the rate of presentations rather than an actual decrease in overdose
deaths (Rosenbaum et al., 2021). To further assess the change in opioid overdoses throughout the
pandemic, EMS calls for service (CFS) in which naloxone was dispensed for suspected overdose
were analyzed. This study in Marion County, Indiana used data from before and after stay-athome orders were put in place (Glober et al., 2020). After the stay-at-home order, there was a
61% increase rate in the administration of naloxone and a 43% increase rate of CFS for
suspected overdose (Glober et al., 2020). Overall, this study found that opioid overdoses
increased by 47% even after the reopening of Indiana, suggesting the increase was due to factors
other than social distancing, like mental health (Glober et al., 2020).
A cross-sectional study conducted by Holland et al. utilized data from the CDC’s
National Syndromic Surveillance Program to broaden what is known about COVID-19’s impact
on ED visits, particularly those related to opioid overdose (Holland et al., 2021). The data used in
the study represent regions of 48 states in America. Trends in ED visits prior to and during the
COVID-19 pandemic, per 100,000 visits were analyzed in this study. Across the United States,
total visits to the emergency department decreased after mitigation measures were introduced in
early March 2020 (Holland et al., 2021). “All drug ODs had a slight decrease from March 29 to
April 11 compared with the same weeks in 2019, but otherwise weekly counts of all drug and
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opioid ODs ranged from 1% to 45% higher in 2020 compared with the same week in 2019”
(Holland et al., 2021). Opioid overdose ED visits did not decrease in the same way that all other
ED visits did when the pandemic began, suggesting an increase in the burden of overdose during
the pandemic (Holland et al., 2021). This study suggests the rise in opioid overdoses can likely
be attributed to persons using drugs alone because of social isolation and limited access to
naloxone or other harm reduction services, in conjunction with other possible effects of the
COVID-19 mitigation measures (Holland et al., 2021).
The policy changes brought on by COVID-19 regarding substance use disorder treatment,
permitted patients to receive treatment while following the CDC’s guidelines. According to the
study by Cales, patient visits for MOUD treatment increased throughout the pandemic,
signifying that people with SUD were able to maintain access to treatment. The study found that
those who relapsed reported “challenges with each of the surveyed obstacles (housing, nutrition,
transportation, employment, and depression) at statistically significant frequencies, ranging from
two to six times, compared to their nonusing counterparts” (Cales et al., 2022). Another study
analyzed changes in dispensing patterns of substance use and mental health medications in the
United States from January 2019 to May 2020 (Jones et al., 2021). Patients receiving
buprenorphine for OUD “increased from 713,778 in January 2019 to 814,019 in May 2020,”
while an “estimated 1,039 fewer patients were dispensed ER intramuscular naltrexone” (Jones et
al., 2021). Patients dispensed naloxone increased from 67,294 to 81,019 (Jones et al., 2021). An
additional study found that the number of existing patients filling buprenorphine prescriptions
changed very little (Currie et al., 2021). New patients entering buprenorphine treatment remained
below the comparative period in 2019 until September 1, 2020 (Currie et al., 2021). The studies
by Cales and Currie indicate that opioid-naïve patients were less likely to receive a prescription
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for opioids during the period from March to May 2020 and patients prescribed buprenorphine
experienced little change to their supply during the pandemic (Cales et al., 2022; Currie et al.,
2021). It is evident that barriers to buprenorphine treatment for existing patients have been
reduced using telemedicine and by increasing the number of doses a patient was allowed to take
home. To assess how the pandemic affected methadone dispensing, a cross-sectional study of the
District of Columbia, thirteen U.S. states, and three Canadian provinces was conducted (Joudrey
et al., 2021). “More than 1 in 10 clinics were not accepting new patients. More than one-third of
clinics not accepting new patients reported that this was due to COVID-19 (Joudrey et al., 2021).
The evidence from this study suggests that COVID-19 made access to methadone more
challenging for new patients seeking treatment.
The trends in dispensing of buprenorphine, naloxone, and methadone demonstrate that
the pandemic limited access to these medications, specifically for new patients. More data on
OUD treatment during the pandemic is needed to advance and maintain access to treatment.

DISCUSSION
The COVID-19 pandemic has significantly impacted the lives of all Americans in many
ways. However, for people with SUD, the effects of the pandemic have proven to be life altering,
and often, life threatening. People with SUD often respond to stress by using drugs. For many of
them, the restrictions during the pandemic and the fear of contracting COVID-19 exacerbated
their normal stress and heightened it to astronomical levels. As pointed out by Warfield et al.
(2021), mental distress that disrupts all aspects of life is a huge concern for PWUD. The COVID19 pandemic disrupted all aspects of life. Galea et al. (2021) discussed the increase in substance
use disorder following disasters of a large scale. The COVID-19 pandemic proved to be a
situation that could be categorized as a large-scale disaster.
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People with SUD depend upon their support groups and treatment programs to remain
clean and avoid overdose. The social distancing requirements and closures/limited hours of many
treatment programs created circumstances that were difficult for many people suffering from
SUD to navigate. In addition, some treatment facilities did not accept new patients due to
complications from the pandemic. Those who lost their jobs found themselves with an increased
amount of spare time, in addition to a decrease in income, which enhanced stress levels and often
resulted in increased drug use. Social distancing requirements often led to isolation which often
provided opportunities for PWUD to use alone, increasing the chance of overdose.
Moving forward, some strategies that were discovered during the pandemic should
continue to be explored to prepare for other possible health crises such as the COVID-19
pandemic in the future. As Cremer et al. (2022) found, during the pandemic, many providers
only offered naltrexone injections once every 45 days instead of every 30 days as was
recommended before the pandemic, a situation that likely left patients more susceptible to
relapse and overdose. It seems it would be beneficial to find ways to provide these injections at
the 30-day mark regardless of social distancing requirements.
As a result of the pandemic, other unprecedented situations arose such as the increased
need for telehealth due to restrictions regarding social distancing and facility closures. Leppla
and Gross (2020) pointed out that the reduction of in-person evaluations for patients needing
buprenorphine treatment provided an advantage over other treatment options. Having such
exceptions in place in the future would be beneficial to those who seek OUD treatment
irrespective of a crisis such as the COVID-19 pandemic.
As stated by Wenger et al. (2021), syringe service programs (SSPs) and harm reduction
services are vital services that help PWUD lessen infectious disease transmission and risky drug-
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using behaviors. To prepare for future crises such as the pandemic, these facilities should receive
access to the funding and staffing resources they need to continue providing the necessary care to
people with SUD.
Lastly, since social isolation has proven to be so detrimental to PWUD, it seems wise to
explore alternative ways to communicate actively during periods of reduced social interactions
such as the establishment of social networks that can function via Zoom or other electronic
means to provide the social support systems that are so vital to people with SUD. Proactive
measures such as these will be crucial to this population especially.

CONCLUSION
Since the late 1990s, over 500,000 people have died from an opioid overdose (CDC,
2021). Felter (2021) reports that opioid overdoses killed nearly 50,000 people in 2019. The CDC
estimates the number of opioid-related overdose deaths to be 69,710 in 2020, an increase of
nearly 19,000 from the previous year (Felter, 2021).
The COVID-19 pandemic adversely affected the lives of most Americans. However,
those with SUD were especially vulnerable due to the increased stress caused by social isolation
and loss of employment, restrictions of social distancing, and decreased treatment options. These
factors exacerbated the ongoing opioid epidemic.
It is evident that existing patients benefitted from the changes in SUD treatment policies,
while new patients found it difficult to initiate treatment. Overall, opioid overdoses were
approximately 38% higher in 2020 than in 2019 (CDC, 2021). Further research is needed to
assess whether the effectiveness of SUD treatment measures during the COVID-19 pandemic
warrants changing the policies long term.
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